Evidence matrix
These scores describe different evidence domains. A strong mechanism cannot compensate for missing human outcomes, and a useful clinical effect need not imply slower biological ageing.
What has been shown in humans?
The available human work includes pilot studies and a relatively small randomised trial. Reported changes span several biomarkers and functional measures, but replication, independent research groups and clinically meaningful endpoints are limited.
What remains uncertain?
Durability, ideal dose, which component contributes most, applicability to well-nourished adults, long-term safety and effects on disease or disability remain unclear.
Doses used in research
Safety and interpretation
- NAC can cause gastrointestinal symptoms and may interact with medicines or clinical conditions.
- The combination has much less long-term safety evidence than either nutrient has individually.
- People using anticoagulants, nitrates, chemotherapy or multiple medicines should seek professional advice before NAC-containing products.
Primary sources and evidence reviews
Small human trial reporting biomarker and functional outcomes; replication is needed.
Exploratory study that helped motivate the later trial.
Editorial note
This dossier was last reviewed on 13 July 2026. Ratings can change when larger trials, adverse-event data or better systematic reviews appear. Corrections should alter the page rather than being buried in a social-media thread.